• We generated a novel monovalent anti-FcγRIII albumin fusion protein that ameliorates antibodymediated murine ITP • Severe adverse events by anti-FcγR antibodies due to FcγR cross-linking is overcome by monovalent FcγR blockade by a first-in-class therapy 
Introduction
Autoimmune anti-platelet antibodies are prevalent among patients with immune thrombocytopenia (ITP) [1] [2] [3] [4] [5] . Antibody-mediated platelet destruction in the majority of ITP patients involves Fc-mediated phagocytosis by macrophages via the Fc gamma receptors (FcγRs) [2] [3] [4] . One of the major activatory FcγRs implicated in platelet depletion is the FcγRIIIA, also a therapeutic target 6 . The first FcγRIIIA-specific monoclonal antibody (mAb) 3G8 was described in 1982 7 , and was later investigated clinically in ITP patients [7] [8] [9] . Encouragingly, more than 50% of ITP patients refractory to other treatments responded with significantly improved platelet counts 8, 10 (approximately 50 kDa) would be a known hindrance to its therapeutic applications, as the in vivo halflife of small proteins decreases as a function of their size 16, 17 . In fact, the Fab fragment of the antihuFcγRIIIA 3G8 had been shown to be ineffective in ameliorating ITP in refractory patients, likely to be due to its very short half-life 11 .
In the present study, we pioneered a novel monovalent FcγR-targeting approach to circumvent the short half-life problems as well as the adverse events associated with the previous anti-FcγRIIIA therapeutics.
We designed and generated a monovalent fusion protein composed of the single chain variable region (scFv) of the anti-FcγRIIIA antibody 3G8 and human serum albumin (HSA), which retained the ability to inhibit IgG-FcγRIIIA interaction in vitro. Furthermore, we generated a monovalent fusion construct for the anti-FcγRIII/IIB antibody 2.4G2, the murine counterpart of 3G8, and demonstrated its in vivo efficacy in ITP amelioration. Importantly, this monovalent construct displayed a notable lack of in vivo adverse events exhibited by its parent antibody, including decreased body temperature and basophil activation.
Therefore, this work demonstrates the proof of concept of monovalent targeting to treat ITP, and hints at its potential to treat other FcγR-mediated autoimmune diseases.
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Methods

Mice
CD-1 female mice (Charles River Laboratories, Kingston, NY, USA) were used for all in vivo experiments. All mice were housed with water and food ad libitum. All animal experiments were approved by the St Michael's Hospital Animal Care and Use Committee.
Antibodies and reagents
Rat IgG2b-FITC isotype control was purchased from Miltenyi Biotech, Canada. Unconjugated monoclonal anti-His antibody (HIS.H8) and AmpliTaq Gold 360 Master Mix were from Life Technologies, Canada. The unconjugated murine FcγRIII/IIB-specific 2.4G2 was from BioX Cell, USA, and the Fab fragment of 2.4G2 was generated using the Fab preparation kit (Life Technologies, Canada).
The anti-huFcγRIIIA 3G8 was from Biolegend, USA. Human serum albumin (HSA) was from Bayer, Canada. IVIg (Privigen) was from CSL Behring, Canada. Human serum IgG (huIgG, I4506) and bovine serum albumin (BSA) were from Sigma, Canada. The staining buffer used for flow cytometry was phosphate buffered saline (PBS) supplemented with 1% FBS, 1 mM EDTA adjusted to pH 7.4. The plasmids encoding the heavy and light chains of 6A6 IgG2a were gifts from Professor Falk Nimmerjahn at the University of Erlangen-Nuremberg, Germany.
Cloning and construction of fusion protein constructs
Total RNA was extracted from the 2.4G2 hybridoma using RNeasy kit (Qiagen, Hungary), and reverse transcription was initiated with oligo dT using RevertAid kit from Fermentas, Hungary. Combinations of forward and reverse primers were tested to identify best fitting sequences judged by the intensity and For personal use only. on October 24, 2017. by guest www.bloodjournal.org From correct size of the polymerase chain reaction (PCR) product. VL sequence was amplified by the VκBackNco-VκFor4 pair, VH was obtained by VH5Cut-γCH3. PCR products were sequenced to confirm correct protein coding framework. Restriction endonuclease sites and linker sequence were introduced during a seconnd PCR step, followed by overlapping extesion PCR joining the VL and VH fragments.
The final 2.4G2 scFv construct had the arrangement VL-(G 4 S) 3 3 -VH) fused to mouse serum albumin (MSA) (Uniprot P07724) via a hexa-glycine linker. Genes containing nucleotide sequences of the 3G8 scFv-HSA or the 2.4G2 scFv-MSA fusion construct were synthesized by GeneArt, USA. The constructs were then cloned into the mammalian expression vector pHLSec encoding a hexahistidine tag using AgeI and KpnI (New England Biolabs, Canada) as described 18 . The soluble domain of huFcγRIIIA (of the high affinity valine158 variant) was cloned into pHLSec as previously described 18 . The nucleotide sequences of all constructs were verified by sequencing (ACGT Corp, Canada).
Recombinant protein expression and purification
The 3G8 scFv-HSA, 2.4G2 scFv-MSA, huFcγRIIIA and 6A6-IgG2a were all expressed by transient expression in HEK293T cells (a gift from Professor Jean-Philippe Julien, University of Toronto, Canada) in a similar fashion as previously described 18, 19 . Briefly, cells were grown to 90% confluence before
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From transfection with polyethylenimine and switched to serum free DMEM media (GE Healthcare, Canada) during recombinant protein expression. Cell culture supernatant was harvested 5 days after transfection and filtered (0.22 µm) before protein purification. Nickel sepharose and protein G agarose (both from GE Healthcare, Canada) were used to purify histidine-tagged recombinant proteins and 6A6-IgG2a respectively.
In vitro binding activity of 3G8 scFv-HSA
The binding activity of 3G8 scFv-HSA for huFcγRIIIA was assessed by enzyme-linked immunosorbent assay. The huFcγRIIIA was coated onto high-binding microtitre plates (Corning, 3590, Canada) at 5 µg/mL overnight at 4 o C. High binding plates are designed to allow maximal adsorption of antigen onto the well surface and are recommended for general enzyme-linked immunosorbent assays. To examine direct binding of 3G8 scFv-HSA for huFcγRIIIA, the plate was blocked using 1% Casein (Life Technologies, Canada) for 1 hour, followed by incubation of serial dilutions of 3G8 scFv-HSA or HSA (highest concentration: 870 nM) for 1.5 hours at room temperature. Bound 3G8 scFv-HSA was detected by anti-human serum albumin-HRP (Abcam, Canada). To examine the ability of 3G8 scFv-HSA to inhibit huIgG binding to huFcγRIIIA, the plate was first blocked with 5% BSA, and then serial dilutions of 3G8 scFv-HSA, HSA (both highest concentration: 650 nM), or 3G8 (highest concentration: 67 nM) was added to wells containing 0.8 µg/mL huIgG. HuIgG was pre-mixed with these inhibitors before being adding to wells coated with huFcγRIIIA and allowed to bind for 1.5 hours at room temperature. Bound huIgG was detected by goat F(ab') 2 anti-human IgG F(ab') 2 -HRP (Abcam, Canada). The 3,3',5,5'-tetramethylbenzidine substrate (Life Technologies, Canada) was used for color development, and color development was stopped by adding 2 M H 2 SO 4 . Absorbance was measured at 450 nm on a Spectramax M5 plate reader (Molecular Devices, California, USA). 
In vivo pharmacokinetics
To examine and compare the in vivo pharmacokinetics of 2. induction, and the platelet number was enumerated by a Z2 particle counter (Beckman Coulter, Canada) as previously described 19 .
Body temperature measurement
Body temperature was used to assess the occurrence of an anaphylactic response induced by different 
Basophil quantification and CD200R3 detection
The level of CD200R3 expression on basophils from peripheral blood was examined using flow cytometry as described 13, 21 . Briefly, mice were bled before treatment, 4 and 24 hours after treatment. 
Statistical analysis
The unpaired, two-tailed student t test was used to assess statistical significance between two data points throughout the study. GraphPad PRISM, Version 6.02 (GraphPad Software, Inc., La Jolla, CA) was used for data analysis.
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Results
HuFcγRIIIA-specific monovalent HSA fusion protein inhibits huIgG binding to huFcγRIIIA
To investigate whether a monovalent 3G8 fused to albumin would retain its specificity, we generated the 3G8 scFv-HSA fusion protein and demonstrated its target specificity towards huFcγRIIIA ( Figure 1A ).
Moreover, we examined its ability to inhibit the interaction between huIgG and huFcγRIIIA. As expected, 3G8 scFv-HSA was able to inhibit the binding of huIgG to huFcγRIIIA in a dose-dependent manner 
Monovalent 2.4G2 scFv-MSA fusion protein targets murine FcγRIII/IIB and exhibits favorable in vivo pharmacokinetics
To investigate the in vivo efficacy and adverse event profile of monovalent targeting, we next generated 2.4G2 scFv-MSA fusion protein, the murine counterpart of 3G8 scFv-HSA that targets murine Figure 3A) , had no effect on 6A6-mediated platelet depletion ( Figure 3B ), demonstrating the expected in vivo specificity of 2.4G2 scFv-MSA. 
The parent antibody 2.4G2, not 2.4G2 scFv-MSA, triggers body temperature decrease
Antibody 2.4G2-induced basophil activation and depletion is absent in response to 2.4G2 scFv-MSA
In addition to changes in body temperature, we examined the basophil activation-related marker CD200R3. A recent report demonstrated that 2.4G2-induced anaphylaxis significantly reduced basophil expression of CD200R3, an activating cell surface receptor 13 . CD200R3 was expressed on basophils ( Figure 5A-B) . The administration of 0.43 nmol (65 µg) 2.4G2 rapidly reduced the ability to detect CD200R3 on basophils, which partially recovered after 24 hours ( Figure 5C ). In contrast, neither 2.4G2 scFv-MSA nor HSA significantly modulated CD200R3 levels. In addition to CD200R3 expression, we observed a transient basophil depletion in response to 2.4G2 administration, which was also largely recovered after 24 hours ( Figure 6 ). In contrast, both 2.4G2 scFv-MSA and HSA had no significant effect on blood basophil levels ( Figure 6 ). In summary, we demonstrate in this work that monovalent targeting of FcγRs is able to ameliorate antibody-mediated ITP while circumventing crosslinking-induced adverse events normally triggered by the FcγR-specific antibody. Fusion of the monovalent antibody domain to albumin has allowed the fusion protein to exhibit favorable pharmacokinetics compared with its Fab counterpart. We speculate that this approach may not only be useful in ITP but may also be beneficial in other FcγR-mediated diseases.
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